Breaking News Instant updates and real-time market news.

AGN

Allergan

$191.14

-0.64 (-0.33%)

07:36
11/22/16
11/22
07:36
11/22/16
07:36

Allergan receives FDA clearance for XEN Gel Stent

Allergan announced the U.S. FDA has cleared the XEN Glaucoma Treatment System for use in the U.S. The XEN Glaucoma Treatment System reduces intraocular pressure in patients and is indicated for the management of refractory glaucomas, where previous surgical treatment has failed or in patients with primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy. XEN is implanted through an ab interno approach and reduces IOP by creating a new drainage channel with a permanent implant that becomes flexible. This provides a new treatment option for the millions of Americans with refractory glaucoma. Allergan plans to launch the XEN Glaucoma Treatment System in the U.S. in early 2017. More than 10,500 XEN Gel Stents have already been distributed worldwide. XEN is CE marked in the European Union, where it is indicated for the reduction of intraocular pressure in patients with primary open angle glaucoma where previous medical treatments have failed. It is also licensed for use in Canada, Switzerland, and Turkey.

  • 29

    Nov

AGN Allergan
$191.14

-0.64 (-0.33%)

11/03/16
LEER
11/03/16
NO CHANGE
Target $266
LEER
Outperform
Allergan price target lowered to $266 from $294 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Allergan to $266 from $294 after the company reported quarterly results modestly missing revenue and EPS targets, with a slowdown in revenue for some of the company's established products leading to a 2016 guidance rebasing. However, Gerberry reiterates an Outperform rating on the shares as he came away from the quarter update encouraged by robust Q3 sales growth from Allergan's more differentiated/cash pay growth drivers.
11/04/16
UBSW
11/04/16
NO CHANGE
Target $240
UBSW
Buy
Allergan price target lowered to $240 from $300 at UBS
UBS analyst Marc Goodman lowered his price target on Allergan to $240 from $300 following disappointing Q3 results and a lowering of his estimates. However, Goodman reiterated his Buy rating on Allergan shares, on the belief it is still a good growth story, has an efficient tax structure and robust pipeline, and has the potential to put up double digit earnings growth for the rest of the decade.
11/21/16
WBLR
11/21/16
INITIATION
Target $209
WBLR
Market Perform
Allergan initiated with a Market Perform at William Blair
William Blair analyst Tim Lugo started Allergan with a Market Perform rating and $209 price target. The analyst views the company as high quality but sees headwinds in 2017 and 2018. Renewed competition for Botox could weigh on out-year estimates while a Namenda generic could come sooner than expected, Lugo tells investors in a research note.
11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

San Francisco Federal…

MDR

McDermott

$7.13

0.3 (4.39%)

, MDSO

Medidata

$79.90

-0.35 (-0.44%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Hot Stocks
Breaking Hot Stocks news story on McDermott, Medidata »

McDermott to replace…

MDR

McDermott

$7.13

0.3 (4.39%)

MDSO

Medidata

$79.90

-0.35 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

BASFY

BASF

$95.05

-0.18 (-0.19%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

BOBE

Bob Evans

$72.53

0.24 (0.33%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Bob Evans management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GLYC

GlycoMimetics

$13.41

1.31 (10.83%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

May Chicago Fed National…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

MDSO

Medidata

$79.90

-0.35 (-0.44%)

, PVTB

PrivateBancorp

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Hot Stocks
Medidata to replace PrivateBancorp in S&P 400 at open on 6/26 »

Canadian Imperial Bank of…

MDSO

Medidata

$79.90

-0.35 (-0.44%)

PVTB

PrivateBancorp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

MFG

Mizuho Financial Group

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Mizuho Financial Group management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

LULU

lululemon

$55.37

1.12 (2.06%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
lululemon management to meet with Barclays »

Meeting with CEO Laurent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AYR

Aircastle

$21.17

0.04 (0.19%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Aircastle management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

EXLS

ExlService

$55.05

0.15 (0.27%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
ExlService management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

NBIX

Neurocrine

$47.35

0.23 (0.49%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Neurocrine management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

GLYC

GlycoMimetics

$13.41

1.31 (10.83%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

XOXO

XO Group

$17.60

0.1 (0.57%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
XO Group management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Durable Goods Orders to be reported at 08:30 »

May Durable Goods Orders…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

June Dallas Fed Mfg…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
JPMorgan life sciences analyst holds an analyst/industry conference call »

Life Science Tools and…

SAVE

Spirit Airlines

$52.55

0.02 (0.04%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Spirit Airlines management to meet with Raymond James »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

May Durable Goods Orders…

04:40
06/26/17
06/26
04:40
06/26/17
04:40
General news
FX Action: The yen is under the cosh »

FX Action: The yen is…

03:10
06/26/17
06/26
03:10
06/26/17
03:10
General news
FX Update: The dollar has traded steady-to-softer »

FX Update: The dollar has…

03:05
06/26/17
06/26
03:05
06/26/17
03:05
General news
FX Action: USD-CAD is softer today »

FX Action: USD-CAD is…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.